CTN Therapy Toolkit | SNMMI

HOME > RESEARCH > Radiopharmaceutical Therapy Central

In This Section

Education

Site Preparation for Establishing 177Lu-Radioligand Therapy Programs

There's a New PET Drug in Town: Manufacturing and Approval Consideration for Your Institution

FDA Categorical THERANOSTICS: Regulatory Considerations for Product Development

3trt image SNMMI/NCI Third Targeted Radionuclide Therapy Conference 2019

Guidance Documents

Site prep thumbnail Charging for Investigational Drugs Under an IND - Questions and Answers
Guidance for Industry - June 2016

PET drug thumbnail Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
Guidance for Industry - June 2016

Therapy Implementation Checklist

RPT Toolkit Checklist (Adobe PDF)

RPT Toolkit Checklist (MS Word)

Publications

Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division

For more articles on nuclear medicine therapy from SNMMI journals, click here.

Technologists' Tools

Site prep thumbnail Nuts and Bolts on New Targeted Radionuclide Therapies: 177Lu-PSMA for Prostate Cancer

Technologist Quarterly Webinar: Lutetium Lu 177 Dotatate Administration in the Nuclear Medicine Department

Clinical Trials Network Webinar Series: Review of Radiopharmaceuticals Used in or for Radionuclide Therapy